Literature DB >> 3978616

Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.

L L Samuels, D M Moccio, F M Sirotnak.   

Abstract

Four folate analogues, methotrexate, aminopterin, 10-deazaminopterin, and 10-ethyl-10-deazaaminopterin were assessed for their ability to be metabolized to poly-gamma-glutamyl derivatives in three tumor lines which vary in their sensitivity to these agents. Cytotoxicity of the four analogues against the murine L1210 leukemia and the human Manca B cell leukemia, as determined by a 3-h clonogenic assay, showed aminopterin and the two 10-deazaaminopterin compounds to be approximately equivalent for each cell type and were 3- to 10- (L1210) and 7- to 14-fold (Manca) more potent than methotrexate. In murine Sarcoma 180 cells, 10-ethyl-10-deazaaminopterin and aminopterin were similarly potent but were 5- to 10-fold more potent than 10-deazaaminopterin and 40- to 80-fold more potent than methotrexate. These results could be explained in part by the differences in transport properties and substrate activities for polyglutamylation for each analogue in these cell types. Initial rates of polyglutamate accumulation of the four analogues, which were determined under conditions of comparable rates of drug entry into the three tumor cell lines, were 7- to 18-fold less than drug entry rates. In L1210 and Sarcoma 180 cells, the relative rates of polyglutamylation were in the order aminopterin greater than 10-ethyl-10-deazaaminopterin greater than methotrexate greater than 10-deazaaminopterin. In contrast, the relative rates of polyglutamylation in Manca cells were in the order 10-ethyl-10-deazaaminopterin approximately equal to aminopterin greater than 10-deazaaminopterin greater than methotrexate, suggesting that folylpolyglutamyl synthetase may have varying substrate preferences in different cell types. The maximum relative extents of total polyglutamate accumulation in L1210 cells were 85 to 95% of the total drug at 24 h. In Manca cells, the maximum polyglutamate accumulation was also 85 to 95%, but this was obtained by 6 h. However, in Sarcoma 180 cells, only aminopterin polyglutamates reached a similar maximum percentage of accumulation, while lower relative polyglutamate levels were achieved with the other analogues. Accumulation of individual polyglutamates in each cell line was similar for all analogues except aminopterin. For methotrexate and the two 10-deazaaminopterins, accumulation occurred mainly as the tetraglutamate or as higher polyglutamates. Aminopterin was accumulated mainly as the diglutamate, particularly in Manca cells where 70% of total drug was in the diglutamate form within the first 3 h and remained the predominant form for 24 h.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978616

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

2.  Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.

Authors:  F Itoh; O Russello; H Akimoto; G P Beardsley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice.

Authors:  M A Bunni; F M Sirotnak; G M Otter; D G Priest
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.

Authors:  K-J Sohn; F Smirnakis; D N Moskovitz; P Novakovic; Z Yates; M Lucock; R Croxford; Y-I Kim
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.